GATC Health's AI Platform Reduces Drug Development Costs and Animal Testing

GATC Health Corp has published a paper titled 'AI in Drug Development: Advancing Capital Efficiency, Reducing Animal Testing, and Driving Precision Medicine,' announced in a press release. The paper highlights how the company's Multiomics Advanced Technology™ (MAT) platform is transforming pharmaceutical development by enhancing speed, cost-effectiveness, and accuracy.

The MAT platform, validated by the University of California, Irvine, boasts predictions with 86% sensitivity and 91% specificity. It employs digital twin models to simulate human biological systems, allowing for the testing of thousands of drug candidates in silico. This approach is 1,000 times faster and significantly more cost-effective than traditional methods.

A key feature of the MAT platform is its ability to reduce reliance on animal testing. By simulating human biology, it supports regulatory shifts like the FDA Modernization Act, potentially replacing animal testing for up to 38.4 million animals annually. This aligns with global trends towards non-animal testing, offering more accurate and humane alternatives.

The paper also discusses how AI-driven preclinical assessments can cut costs by up to 90%, reducing the time to file an Investigational New Drug (IND) application from over a decade to under two years. GATC Health's advancements promise to deliver better, safer treatments to patients more quickly, addressing key challenges in the drug development industry.